Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer

Astellas and Seattle Genetics now expect key top-line data on their antibody-drug conjugate in urothelial cancer in the first half of next year, as pivotal trials in support of a planned US accelerated approval progress.